Cover Story
In 2010, John Knox Singleton, the CEO of the Inova Health System, had several meetings with John Niederhuber, a surgeon and scientist who had just been replaced as NCI director.
By Matthew Bin Han Ong
In Brief
Drugs & Targets
Trending Stories
- Karen Knudsen to leave ACS
- A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease
- Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies - Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Mace Rothenberg’s museum will tell the stories behind breakthroughs in medicine
- Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation